CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 86 enrolled
Drug / intervention
SAGE-718-matching placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05318937
NCT05318937Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Parkinson's Disease Cognitive Impairment

Supernus Pharmaceuticals, Inc.·interventional·Posted Apr 8, 2022·Updated Sep 12, 2025

In Brief

A Phase 2 clinical trial evaluating SAGE-718-matching placebo and SAGE-718 for Parkinson Disease and Cognitive Dysfunction. Completed, enrolled 86 participants across 38 sites.

Detailed Summary

The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Parkinson's disease mild cognitive impairment (PD-MCI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease, Cognitive Dysfunction
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedApr 8, 2022
Enrollment StartJun 6, 2022
Primary CompletionJan 17, 2024
Study CompletionFeb 23, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.2 years ago

Interventions

SAGE-718-matching placebodrug

Oral capsules

SAGE-718drug

Oral capsules